• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JACC Cardiovasc Imaging . Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers

tetano

Editor, Senior Moderator
JACC Cardiovasc Imaging


. 2021 May 5;S1936-878X(21)00356-9.
doi: 10.1016/j.jcmg.2021.04.011. Online ahead of print.
Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers


George Joy[SUP] 1 [/SUP], Jessica Artico[SUP] 1 [/SUP], Hibba Kurdi[SUP] 1 [/SUP], Andreas Seraphim[SUP] 1 [/SUP], Clement Lau[SUP] 2 [/SUP], George D Thornton[SUP] 1 [/SUP], Marta Fontes Oliveira[SUP] 3 [/SUP], Robert Daniel Adam[SUP] 4 [/SUP], Nikoo Aziminia[SUP] 5 [/SUP], Katia Menacho[SUP] 1 [/SUP], Liza Chacko[SUP] 6 [/SUP], James T Brown[SUP] 6 [/SUP], Rishi K Patel[SUP] 6 [/SUP], Hunain Shiwani[SUP] 1 [/SUP], Anish Bhuva[SUP] 1 [/SUP], Joao B Augusto[SUP] 7 [/SUP], Mervyn Andiapen[SUP] 8 [/SUP], Aine McKnight[SUP] 9 [/SUP], Mahdad Noursadeghi[SUP] 10 [/SUP], Iain Pierce[SUP] 1 [/SUP], Timoth?e Evain[SUP] 11 [/SUP], Gabriella Captur[SUP] 12 [/SUP], Rhodri H Davies[SUP] 1 [/SUP], John P Greenwood[SUP] 13 [/SUP], Marianna Fontana[SUP] 6 [/SUP], Peter Kellman[SUP] 14 [/SUP], Erik B Schelbert[SUP] 15 [/SUP], Thomas A Treibel[SUP] 1 [/SUP], Charlotte Manisty[SUP] 1 [/SUP], James C Moon[SUP] 16 [/SUP], COVIDsortium Investigators



Affiliations

Abstract

Objectives: The purpose of this study was to detect cardiovascular changes after mild severe acute respiratory syndrome coronavirus 2 infection.
Background: Concern exists that mild coronavirus disease 2019 may cause myocardial and vascular disease.
Methods: Participants were recruited from COVIDsortium, a 3-hospital prospective study of 731 health care workers who underwent first-wave weekly symptom, polymerase chain reaction, and serology assessment over 4 months, with seroconversion in 21.5% (n = 157). At 6 months post-infection, 74 seropositive and 75 age-, sex-, and ethnicity-matched seronegative control subjects were recruited for cardiovascular phenotyping (comprehensive phantom-calibrated cardiovascular magnetic resonance and blood biomarkers). Analysis was blinded, using objective artificial intelligence analytics where available.
Results: A total of 149 subjects (mean age 37 years, range 18 to 63 years, 58% women) were recruited. Seropositive infections had been mild with case definition, noncase definition, and asymptomatic disease in 45 (61%), 18 (24%), and 11 (15%), respectively, with 1 person hospitalized (for 2 days). Between seropositive and seronegative groups, there were no differences in cardiac structure (left ventricular volumes, mass, atrial area), function (ejection fraction, global longitudinal shortening, aortic distensibility), tissue characterization (T[SUB]1[/SUB], T[SUB]2[/SUB], extracellular volume fraction mapping, late gadolinium enhancement) or biomarkers (troponin, N-terminal pro-B-type natriuretic peptide). With abnormal defined by the 75 seronegatives (2 SDs from mean, e.g., ejection fraction <54%, septal T[SUB]1[/SUB] >1,072 ms, septal T[SUB]2[/SUB] >52.4 ms), individuals had abnormalities including reduced ejection fraction (n = 2, minimum 50%), T[SUB]1[/SUB] elevation (n = 6), T[SUB]2[/SUB] elevation (n = 9), late gadolinium enhancement (n = 13, median 1%, max 5% of myocardium), biomarker elevation (borderline troponin elevation in 4; all N-terminal pro-B-type natriuretic peptide normal). These were distributed equally between seropositive and seronegative individuals.
Conclusions: Cardiovascular abnormalities are no more common in seropositive versus seronegative otherwise healthy, workforce representative individuals 6 months post-mild severe acute respiratory syndrome coronavirus 2 infection.

Keywords: COVID-19; SARS-CoV-2; cardiovascular magnetic resonance; late gadolinium enhancement; myocardial edema; myocarditis; troponin.
 
Back
Top Bottom